Table 1.
Baseline characteristics and outcome stratified by strictly achieving blood pressure target of ≤160/90 mmHg during the first 24 h after MT.
| Variable | BP ≤ 160/90 mmHg “low‐BP” (n = 35) | BP > 160/90 mmHg “high BP” (n = 130) | p‐value |
|---|---|---|---|
| Patient characteristics | |||
| Age | 73.0 ± 13.1 | 72.8 ± 12.5 | 0.924 |
| Male sex | 21/35 (60%) | 60/130 (46.2%) | 0.146 |
| Arterial hypertension | 27/35 (77.1%) | 103/130 (79.2%) | 0.789 |
| Diabetes mellitus | 11/35 (31.4%) | 30/130 (23.1%) | 0.310 |
| Dyslipidemia | 17/35 (48.6%) | 65/130 (50.0%) | 0.881 |
| Atrial fibrillation | 13/35 (27.1%) | 58/130 (44.6%) | 0.428 |
| Active smoking | 4/35 (11.4%) | 16/130 (12.3%) | 0.888 |
| Heart failure | 6/35 (17.1%) | 19/130 (14.6%) | 0.711 |
| Coronary artery disease | 9/35 (25.7%) | 17/130 (13.1%) | 0.069 |
| Admission blood pressure (syst/diast) | 144.0 ± 28.7/74.3 ± 18.4 | 152.3 ± 22.7/83.5 ± 15.2 | 0.169/0.010 |
| 145 [124–165.5]/80 [60.5–84] (n = 123) | 150 [139–163]/82 [70–92] (n = 33) | ||
| Admission MAP | 97.5 ± 19.9 | 106.4 ± 15.5 | 0.028 |
| 100.3 [83.3–110.5] | 106.7 [96.7–116.7] | ||
| Antihypertensive baseline medication | |||
| Any antihypertensive medication | 23/35 (65.7%) | 87/130 (66.9%) | 0.893 |
| ACE‐inhibitor | 16/35 (45.7%) | 63/130 (48.5%) | 0.773 |
| Beta‐receptor blocker | 13/35 (37.1%) | 67/130 (51.5%) | 0.130 |
| Hydrochlorothiazide | 5/35 (14.3%) | 26/130 (20.0%) | 0.442 |
| Loop diuretics | 12/35 (34.3%) | 23/130 (17.7%) | 0.033 |
| Calcium antagonist | 5/35 (14.3%) | 28/130 (21.5%) | 0.341 |
| Aldosterone antagonist | 2/35 (5.7%) | 6/130 (4.6%) | 0.678 |
| Alpha‐receptor blocker | 0/35 (0.0%) | 5/130 (3.8%) | 0.585 |
| Stroke characteristics | |||
| Admission NIHSS | 15 (11–17) (n = 35) | 14 (8–18) (n = 128) | 0.197 |
| Location of occlusion | |||
| Internal carotid artery | 7/35 (20.0%) | 24/130 (18.5%) | 0.836 |
| Anterior cerebral artery | 1/35 (2.9%) | 4/130 (3.1%) | 0.946 |
| Middle cerebral artery (M1) | 18/35 (51.4%) | 62/130 (47.7%) | 0.695 |
| Middle cerebral artery (M2) | 10/35 (28.6%) | 35/130 (26.9%) | 0.846 |
| Posterior cerebral artery | 2/35 (5.7%) | 3/130 (2.3%) | 0.297 |
| Basilar artery | 5/35 (14.3%) | 16/130 (12.3%) | 0.755 |
| Vertebral artery | 1/35 (2.9%) | 1/130 (0.8%) | 0.380 |
| ASPECTS pre‐intervention | 10 (8–10) (n = 33) | 10 (9–10) (n = 128) | 0.168 |
| Treatment parameters | |||
| Intravenous thrombolysis | 15/35 (42.9%) | 73/130 (56.2%) | 0.162 |
| Admission to IVT (minutes) | 32 (16–55) (n = 6) | 27 (19–40) (n = 46) | 0.886 |
| Symptom onset to groin puncture (minutes) | 183 (130–321) (n = 26) | 192 (131–245) (n = 92) | 0.790 |
| Symptom onset to recanalization (minutes) | 248 (180–348) (n = 24) | 245 (189–318) (n = 87) | 0.753 |
| General anesthesia | 15/35 (42.9%) | 42/129 (32.6%) | 0.256 |
| Outcome parameters | |||
| Final infarct volume [mm3] | 13.7 (0.4–30.1) (n = 20) | 4.9 (0–20.2) (n = 71) | 0.297 |
| sNfL 3 days after MT [pg/mL] | 239.7 (168.4–303.4) (n = 13) | 118.8 (52.5–220.5) (n = 63) | 0.026 |
| Discharge mRS | 4 (3–5) (n = 35) | 2 (1–5) (n = 130) | 0.032 |
| Discharge NIHSS | 6 (2–14) (n = 30) | 2 (1–8) (n = 113) | 0.016 |
| 90‐day mRS | 4 (3–6) (n = 35) | 2 (0–5) (n = 130) | 0.002 |
| 90‐day mRS ≤ 2 | 7/35 (20.0%) | 70/130 (53.8%) | <0.001 |
| 90‐day MoCA | 18 (14–21) (n = 6) | 19 (15–21) (n = 65) | 0.909 |
| 90‐day EQ‐5D‐3L index | 0.45 ± 0.28 (n = 24) | 0.63 ± 0.31 (n = 106) | 0.009 |
Data is displayed as absolute number/number of available data (%) or mean ± SD or median (IQR) (number of observations available). Significant differences are marked bold.
ASPECTS, Alberta stroke program early CT score; BP, blood pressure; EQ‐5D‐3L, European quality of life index version 5D‐3L; MAP, mean arterial pressure; MT, mechanical thrombectomy; M1, M1 segment; M2, M2 segment; NIHSS, National Institutes of Health Stroke Scale; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin Scale score; sNfL, serum neurofilament light chain.